CPHI North America, the only gathering in the pharmaceutical industry, encompassing the entire spectrum of drug research, production, and packaging, has come to a thrilling close. From May 7th to 9th, 2024.

The Industry and Information Technology Department of Hebei Province has released the list of the first batch of innovative small and medium-sized enterprises (SMEs) for 2024. Laviana Pharma (Cangzhou) Co., Ltd. has been recognized as an innovative SME due to its strong research and development capabilities in the pharmaceutical industry and its provision of manufacturing services (CDMO).

​On March 18th through March 21st, 2024 (local time), DCAT Week 2024 (the annual meeting of the Drug, Chemical & Allied Trades Association that has been highly recognized in the industry was grandly held in New York, U.S.A.

Recently, Tianjin Industrial and Information Technology Bureau released the second batch of the 2023 Specialized and New Small and Medium-sized Enterprises. Laviana Pharma was included in the list for its exceptional performance in pharmaceutical research and development, as well as manufacturing services.

On December 28,2023, Laviana Pharma was recognized as "Jiangsu Provincial Enterprise Technology Center" by five departments including Industry and Information Technology Department of Jiangsu, Jiangsu Development & Reform Commission, Jiangsu Provincial Department of Science and Technology, Department of Finance of Jiangsu Province, and Jiangsu Provincial Tax Service. It is indicated by this honor Laviana Pharma has entered a new stage in technological innovation, high-level innovative talent cultivation, innovative achievements transformation, etc.

On January 3, 2024, a delegation from the Hebei Tsinghua Development Research Institute visited the Cangzhou Lingang Economic Development Zone in Hebei. They conducted comprehensive research at both the Chemical Pharmaceutical Research and Development Public Experimental Platform and Laviana Pharma's Cangzhou GMP Production Plant. During the visit, leaders from both sides engaged in extensive discussions on promoting high-quality development in the biopharmaceutical industry within the Beijing-Tianjin-Hebei region.